New hope for rare blood cancers? immune therapy trial seeks to tame disease
NCT ID NCT07468916
Summary
This study is testing a long-acting immune therapy drug called ropeginterferon alfa-2b for adults with rare, overlapping blood cancers like chronic myelomonocytic leukemia (CMML). The main goals are to find a safe and effective dose and to see if the drug can control the disease and improve symptoms. About 35 participants will receive injections and be closely monitored for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.